$CRIS

Why Did Curis (CRIS) Stock Soar After Hours? - Curis (NASDAQ:CRIS)

Curis Inc. (NASDAQ:CRIS) shares rose 8.51% to $0.46 after hours Wednesday after the company confirmed its previously approved reverse stock split will take effect Thursday at 5:00 p.m. ET, with split-adjusted trading starting Jul. 6. Shareholders approved a 1-for-5 to 1-for-25 split to help regain Nasdaq’s $1 bid compliance.

Original reporting
Published Jul 2, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 9:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CRIS
Neutral
medium confidence
Mentioned
$CRIS
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CRISNeutralMed
01

Why it matters

The confirmed effective time and the start of split-adjusted trading explain the after-hours surge and set the next mechanical catalyst for liquidity/price normalization.

02

Market read

This is a time-specific corporate action confirmation that can drive short-term trading volatility and technical positioning.

03

What to watch

Traders may overreact to the percentage move; the key is split-adjusted trading mechanics and Nasdaq compliance optics, not new fundamentals.

Relevance 6/10Novelty 6/10Timing: After-hours today; split effective 5:00 p.m. ET Thursday and split-adjusted trading begins Jul. 6.

Background

Curis previously received approval for a reverse stock split to address Nasdaq’s $1.00 minimum bid price rule.

Company-level read

Ticker impact

$CRISNeutralMedium confidence
Context

Curis shares jumped after-hours as the company confirmed its previously approved reverse stock split would take effect Thursday.

Expected impact

Near-term volatility likely around the split-adjusted trading start (Jul. 6), with price action driven more by mechanics than fundamentals.

Evidence & confidence

The article cites an SEC filing confirming the split effective time and that trading continues under CRIS, but provides no new operating/financial catalyst.

Market effects

Limited sector read-through; this is a microcap compliance/corporate-action event rather than biotech-specific news.

No clear regional spillover beyond US microcap/Nasdaq compliance dynamics.

Low; reverse-split mechanics are company-specific and not tied to global biotech developments.

Counterpoint

A reverse split can temporarily lift the tape/price level, but it does not reduce underlying business risk or dilution/financing needs.

Key entities

  • Curis, Inc.

    NASDAQ-listed biotech confirming its approved reverse stock split takes effect Thursday and begins split-adjusted trading Jul. 6.

  • Nasdaq $1.00 minimum bid price rule

    Compliance threshold Curis is targeting via the reverse split.

Related articles

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

$SFLMedAI 8/10

Newbuild order for two very large ammonia acriers in combination with long term time charters

SFL Corporation ordered two 93,000 cbm ammonia carriers for $216 million, deliverable in 2028. The company also secured long-term charters with an oil major, adding $162 million to its backlog. CEO Ole B. Hjertaker highlighted the investment's accretive nature and the charterer's investment-grade status. The total fixed-rate charter backlog for 2026 exceeds $1.3 billion.

$CVXLow

Chevron announces senior leadership changes

Chevron (CVX) announced senior leadership changes effective January 1, 2027. Mark Nelson will focus on strategy and business development, Eimear Bonner will lead Oil, Products & Gas, Jeff Gustavson will become CFO, and Brent Gros will head New Energies and AI strategy. CEO Mike Wirth praised the new leaders' expertise and commitment.